NCT01414088

Brief Summary

The kidneys have numerous salt and water channels and play a major role in the regulation of sodium and water. We do not know how these channels work in certain water and sodium accumulating medical conditions. The purpose of this study is to identify and measure the activity in the water and sodium channels by measuring urine biomarkers/proteins in young healthy subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 9, 2011

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 11, 2011

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
Last Updated

May 20, 2013

Status Verified

May 1, 2013

Enrollment Period

1 year

First QC Date

August 9, 2011

Last Update Submit

May 17, 2013

Conditions

Keywords

NephrologyENaCNCCNKCCSodium channelsrenal biomarkers

Outcome Measures

Primary Outcomes (1)

  • Renal biomarkers

    Urinary epithelial sodium channels (ENaC), Sodium-Chloride transporters (NCC), Sodium-potassium-2chloride transporters (NKCC) and aquaporin2 channels (AQP2) before, during and after fluid infusion

    day one

Secondary Outcomes (1)

  • blood hormones regulating salt, water and blood pressure

    day one

Study Arms (3)

glucose

PLACEBO COMPARATOR

glucose 5 %

Other: glucose 5%

isotonic saline

ACTIVE COMPARATOR

isotonic saline 0.9 mg/ml

Other: isotonic saline 0,9 mg/ml

hypertonic saline

ACTIVE COMPARATOR

hypertonic saline 2.9 mg/ml

Other: hypertonic saline 2,9 mg/ml

Interventions

infusion, 23 ml/kg, during 50 minutes

Also known as: isotonic saline
isotonic saline

infusion, 7 ml/kg, during 50 minutes

Also known as: hypertonic saline
hypertonic saline

infusion, 23 ml/kg, during 50 minutes

Also known as: glucose 5 %
glucose

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy males and females
  • age 18-45
  • BMI range 18,5-30,0 kg/m2

You may not qualify if:

  • hypertension (ie ambulatory BP \>130 mmHg systolic or/and \>80 mmHg diastolic)
  • history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic disease.
  • alcohol abuse
  • drug abuse
  • smoking
  • pregnancy or nursing
  • blood donation within a month prior to examination
  • Medical treatment apart from oral contraception

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medicinsk Forskning, Regionshospitalet i Holstebro

Holstebro, 7500, Denmark

Location

Related Publications (1)

  • Jensen JM, Mose FH, Bech JN, Nielsen S, Pedersen EB. Effect of volume expansion with hypertonic- and isotonic saline and isotonic glucose on sodium and water transport in the principal cells in the kidney. BMC Nephrol. 2013 Sep 26;14:202. doi: 10.1186/1471-2369-14-202.

MeSH Terms

Conditions

Kidney Diseases

Interventions

Sodium ChlorideSaline Solution, Hypertonic

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsHypertonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Erling B Pedersen, Professor

    Medicinsk Forskning, Regionshospitalet i Holstebro

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
DMSc

Study Record Dates

First Submitted

August 9, 2011

First Posted

August 11, 2011

Study Start

April 1, 2011

Primary Completion

April 1, 2012

Study Completion

April 1, 2012

Last Updated

May 20, 2013

Record last verified: 2013-05

Locations